Search
The effects of adoptive T cell therapy on mesothelioma and metastatic lung and breast cancers are the focus of a new Memorial Sloan Kettering Cancer Center trial, which, compared to some existing trials of therapy, offers some important differences for patients.
Maria Jasin, a member of the Sloan Kettering Institute’s Developmental Biology Program, discusses her research.
This year, the GSK student-run Experimental Therapeutics Symposium highlighted MSK’s expertise in successfully moving novel therapies from bench to bedside.
A new lung cancer research center has been created at Memorial Sloan Kettering Cancer Center (MSK). The Fiona and Stanley Druckenmiller Center for Lung Cancer Research (DCLCR) is a multidisciplinary research initiative dedicated to developing innovative and more-effective treatments for people with lung cancer.
MSK medical oncologist David Straus is looking for less-intensive treatments for Hodgkin lymphoma, a type of blood cancer most commonly found in young adults.
The online resource will serve as a benchmark for researchers studying metabolism and cancer.
Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.
Mark Denisiuk was diagnosed with acute myeloid leukemia in the spring of 2021. He found hope when he enrolled in an early trial of an entirely new kind of drug that’s based on lab research conducted at MSK.
Nine students will don caps and gowns to celebrate their academic achievements and receive their PhDs from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).
Discover how Sunrise Association Day Camps are transforming summer for children affected by cancer.